Global Ileal Bile Acid Transporter (IBAT) Inhibitor Market Size, Share & Trends Analysis Report By Drug Type (Odevixibat, Maralixibat, Linerixibat, Volixibat, Elobixibat, Pipeline Molecules), By Indication (Progressive Familial Intrahepatic Cholestasis [PFIC], Alagille Syndrome, Primary Biliary Cholangitis, Biliary Atresia, Primary Sclerosing Cholangitis, Intrahepatic Cholestasis of Pregnancy, Non-Alcoholic Steatohepatitis, Chronic Idiopathic Constipation), By Patient Type (Pediatric, Adult), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Pediatric Hepatology Centers, Gastroenterology & Hepatology Clinics, Academic Medical Centers, Specialty Hospitals), and By Region (North America, Europe, APAC, Middle East & Africa, LATAM) – Forecasts, 2026–2034

Table of Contents

1. Introduction
   1.1. Market Introduction
   1.2. Research Methodology
   1.3. Estimation Methodology
   1.4. IBAT Inhibitor Market Ecosystem Overview
   1.5. Market Classification & Scope
   1.6. Geographic Scope
   1.7. Study Years
2. Executive Summary
   2.1. Market Snapshot
   2.2. Key Findings
   2.3. Opportunity Assessment
   2.4. Analyst Perspective
3. Market Dynamics
   3.1. Market Drivers
   3.1.1. Regulatory Approvals Validating IBAT Inhibition Therapy
   3.1.2. Expansion of Clinical Pipeline into Adult Cholestatic Diseases
   3.1.3. Precision Medicine & Genetic Screening Integration
   3.2. Market Restraints
   3.2.1. Premium Pricing & Reimbursement Challenges
   3.2.2. Gastrointestinal Adverse Effects Affecting Adherence
   3.2.3. Limited Access in Emerging Economies
   3.3. Market Opportunities
   3.3.1. Expansion into MASH/NASH & Metabolic Liver Diseases
   3.3.2. Label Expansion Across Cholestatic Disorders
   3.3.3. Combination Therapy Development
   3.4. Emerging Trends
   3.4.1. Biomarker-Based Treatment Optimization
   3.4.2. Rare Disease Genetic Screening Programs
   3.4.3. Real-World Evidence & Patient Registry Expansion
4. Global IBAT Inhibitor Market Analysis & Forecast (2025–2034)
   4.1. Market Revenue Forecast
   4.2. Mechanism of Action Analysis
   4.3. Clinical Efficacy Benchmarking
   4.4. Pipeline Assessment & Trial Landscape
   4.5. Rare Disease Patient Population Analysis
   4.6. Pricing & Reimbursement Analysis
   4.7. Porter’s Five Forces Analysis
   4.8. PESTLE Analysis
   4.9. Value Chain Analysis
5. Market Segmentation
   5.1. By Drug Type
   5.1.1. Odevixibat (Bylvay)
   5.1.2. Maralixibat (Livmarli)
   5.1.3. Linerixibat
   5.1.4. Volixibat
   5.1.5. Elobixibat (Goofice)
   5.1.6. Other Pipeline Molecules

5.2. By Indication
5.2.1. Progressive Familial Intrahepatic Cholestasis (PFIC)
5.2.2. Alagille Syndrome
5.2.3. Primary Biliary Cholangitis
5.2.4. Biliary Atresia
5.2.5. Primary Sclerosing Cholangitis
5.2.6. Intrahepatic Cholestasis of Pregnancy
5.2.7. Non-Alcoholic Steatohepatitis/MASH
5.2.8. Chronic Idiopathic Constipation
5.2.9. Other Cholestatic Liver Diseases

5.3. By Patient Type
5.3.1. Pediatric
5.3.2. Adult

5.4. By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Specialty Pharmacies
5.4.3. Retail Pharmacies
5.4.4. Online/Mail-Order Pharmacies

5.5. By End-User
5.5.1. Pediatric Hepatology Centers
5.5.2. Gastroenterology & Hepatology Clinics
5.5.3. Academic Medical Centers
5.5.4. Specialty Hospitals
5.5.5. Rare Disease Treatment Centers

5.6. By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. Middle East & Africa
5.6.5. Latin America

6. Regional Market Overview
   6.1. North America
   6.1.1. United States
   6.1.2. Canada

6.2. Europe
6.2.1. Germany
6.2.2. United Kingdom
6.2.3. France
6.2.4. Italy
6.2.5. Spain
6.2.6. Netherlands
6.2.7. Sweden
6.2.8. Rest of Europe

6.3. Asia Pacific
6.3.1. Japan
6.3.2. China
6.3.3. India
6.3.4. Australia
6.3.5. South Korea
6.3.6. Rest of Asia Pacific

6.4. Middle East & Africa
6.4.1. UAE
6.4.2. Saudi Arabia
6.4.3. South Africa
6.4.4. Rest of Middle East & Africa

6.5. Latin America
6.5.1. Brazil
6.5.2. Mexico
6.5.3. Rest of Latin America

7. Competitive Landscape
   7.1. Competitive Benchmarking
   7.2. Revenue & Market Share Analysis
   7.3. Product Portfolio Comparison
   7.4. Pipeline Positioning Analysis
   7.5. Strategic Partnerships & Acquisitions
   7.6. Regulatory & Commercial Strategies
   7.7. Company Profiles
8. Company Profiles
   8.1. Mirum Pharmaceuticals Inc.
   8.2. Ipsen S.A.
   8.3. GlaxoSmithKline plc
   8.4. EA Pharma Co., Ltd.
   8.5. Intercept Pharmaceuticals Inc.
   8.6. Travere Therapeutics Inc.
   8.7. CymaBay Therapeutics Inc.
   8.8. Takeda Pharmaceutical Company Limited
   8.9. Pfizer Inc.
   8.10. Novartis AG
   8.11. Gilead Sciences Inc.
   8.12. Genfit S.A.
   8.13. Enanta Pharmaceuticals Inc.
   8.14. AstraZeneca plc
9. Technology & Innovation Trends
   9.1. IBAT/ASBT Inhibition Mechanisms
   9.2. Genetic Testing & Precision Medicine Integration
   9.3. Biomarker Monitoring Technologies
   9.4. Oral Drug Delivery Innovations
   9.5. AI-Based Rare Disease Diagnosis Platforms
   9.6. Real-World Evidence & Digital Patient Monitoring
10. Regulatory Landscape
    10.1. FDA Orphan Drug Regulations
    10.2. EMA Rare Disease Approval Framework
    10.3. Priority Review & Breakthrough Therapy Designations
    10.4. Pediatric Exclusivity Programs
    10.5. Reimbursement & HTA Landscape
    10.6. Rare Disease Access Policies
11. Recent Developments
    11.1. Linerixibat Phase III Trial Updates
    11.2. Maralixibat Label Expansion
    11.3. Odevixibat Long-Term Data Release
    11.4. Combination Therapy Clinical Studies
    11.5. EMA Expanded Approvals

12. Market Research Findings & Conclusion

13. Disclaimer